María Victoria
Mateos Manteca
Profesora Titular de Universidad
Memorial Sloan Kettering Cancer Center
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (32)
2024
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Blood Advances, Vol. 8, Núm. 2, pp. 388-398
2023
-
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 4, pp. 711-722
-
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 5, pp. 385-393
-
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Leukemia and Lymphoma
-
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748
-
Global disparities in patients with multiple myeloma: a rapid evidence assessment
Blood Cancer Journal, Vol. 13, Núm. 1
-
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood cancer journal, Vol. 13, Núm. 1, pp. 116
-
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 19, Núm. 12, pp. 811-818
2022
-
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
Haematologica, Vol. 107, Núm. 10, pp. 2408-2417
-
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Frontiers in Oncology, Vol. 12
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Blood cancer journal, Vol. 12, Núm. 2, pp. 32
-
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
2021
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767
-
Minimal residual disease in Myeloma: Application for clinical care and new drug registration
Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212
2020
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 396, Núm. 10245, pp. 186-197
-
Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma
Value in Health, Vol. 23, Núm. 4, pp. 441-450
-
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis
Clinical Lymphoma, Myeloma and Leukemia, Vol. 20, Núm. 1, pp. e30-e37